Peptide News Calendar: What to Watch Through 2027
This is a living guide to the dates that matter in peptide regulation, drug development and industry news. We update it regularly.
Regulatory
- July 23-24, 2026: The FDA’s Pharmacy Compounding Advisory Committee voted on seven peptides and recommended six, including BPC-157, TB-500 and KPV. The votes are advisory, and the FDA still has to act. See the full results and what happens next.
- Before February 2027: A later committee meeting is expected to consider LL-37, Dihexa acetate, injectable GHK-Cu, PEG-MGF and Melanotan II.
- Ongoing: The FDA continues to act on misleading marketing of compounded GLP-1 products, including warning letters to dozens of telehealth companies in 2026.
Drug pipeline
- Q1 2027: Eli Lilly plans to submit its Biologics License Application for retatrutide.
- Late 2027 to 2028: The earliest likely retatrutide decision, if the filing goes as planned.
- 2026-2027: Oral GLP-1 competition continues with the Wegovy pill and Foundayo on the market and oral VK2735 in development.
Industry
- Samsung Biologics announced a tender offer for peptide manufacturer PolyPeptide Group on July 20, 2026.
- Employer coverage of GLP-1s for weight loss has stalled at about 36% of employers in 2026, per an industry survey, and Medicare began a GLP-1 Bridge demonstration on July 1, 2026.
FAQ
When will retatrutide be filed with the FDA?
Eli Lilly announced on July 23, 2026 that it plans to submit a Biologics License Application in the first quarter of 2027.
What peptides will the FDA committee review next?
LL-37, Dihexa acetate, injectable GHK-Cu, PEG-MGF and Melanotan II are expected to go to a later advisory committee meeting before February 2027.
Sources: Drugs.com; Epocrates (July 24, 2026); Goodwin Procter via Mondaq (April 15, 2026); PolyPeptide Group investor news; GoodRx.
This article is for general news and education. It is not medical or legal advice. Talk to a licensed clinician about any treatment decision.
